A significant international research initiative has illuminated a striking divergence in how individuals experience the neurological and psychological sequelae of COVID-19, commonly referred to as "long COVID." The findings indicate that patients in the United States report a considerably higher prevalence of cognitive impairments, often termed "brain fog," alongside psychological distress such as depression and anxiety, when contrasted with their counterparts in lower and middle-income nations, including India and Nigeria. This revelation, derived from a comprehensive study spearheaded by Northwestern Medicine, suggests that socioeconomic factors, cultural norms surrounding health disclosure, and differential access to healthcare services, rather than inherent biological variations in the illness’s severity, are the primary drivers behind these observed disparities. The implications of this research are profound, hinting at a potentially vast, yet largely undocumented, population globally grappling with these debilitating post-viral conditions.
This groundbreaking research represents the inaugural cross-continental comparative analysis specifically examining the neurological and cognitive symptoms of long COVID. The investigation meticulously followed over 3,100 adults diagnosed with long COVID, who were undergoing evaluation at prominent academic medical centers situated in Chicago, USA; Medellín, Colombia; Lagos, Nigeria; and Jaipur, India. A notable aspect of the participant cohort is that the majority had not been hospitalized during their initial SARS-CoV-2 infection, underscoring the widespread impact of long COVID even among those with less severe acute illness. Within this non-hospitalized group, a staggering 86% of patients in the United States reported experiencing symptoms of brain fog. In stark contrast, the reported incidence of brain fog was significantly lower in other participating regions: 63% in Nigeria, 62% in Colombia, and a mere 15% in India.
A similar pattern emerged when assessing mental health symptoms. Nearly three-quarters of non-hospitalized long COVID patients in the U.S. disclosed experiencing symptoms of depression or anxiety. This figure saw a substantial reduction in Colombia, where approximately 40% of patients reported similar distress. In Nigeria and India, the proportion of patients reporting comparable psychological challenges fell below 20%. These marked differences underscore the complex interplay between a medical condition and the societal and cultural contexts in which it is experienced and reported.
Dr. Igor Koralnik, the senior author of the study and a leading figure in neuro-infectious diseases and global neurology at Northwestern University Feinberg School of Medicine, offered crucial insights into the root causes of these discrepancies. He posited that the observed variations are largely attributable to cultural factors influencing the willingness and ability of individuals to discuss their health. "It is culturally accepted in the U.S. and Colombia to talk about mental health and cognitive issues, whereas that is not the case in Nigeria and India," Dr. Koralnik explained. This cultural acceptance, he elaborated, facilitates more open reporting of symptoms. Conversely, in cultures where discussing mood disorders or cognitive difficulties might be less common or even discouraged, individuals may be less inclined to report these issues.
Furthermore, Dr. Koralnik highlighted that a combination of factors, including cultural denial of certain symptoms, stigma associated with mental health conditions, prevailing societal misperceptions, the influence of religiosity and established belief systems, and varying levels of health literacy, could collectively contribute to biased reporting. The availability and accessibility of mental healthcare services also play a pivotal role. In regions with a scarcity of mental health providers and a perceived lack of effective treatment options, individuals may be less likely to seek help or report symptoms, further exacerbating the disparity in reported experiences. This nuanced perspective shifts the focus from a purely biological interpretation of long COVID’s impact to a more holistic understanding that incorporates psychosocial dimensions.
Across all geographical regions included in the study, a consistent set of neurological symptoms was identified as being most frequently reported by individuals experiencing long COVID. These common complaints included brain fog, persistent fatigue, myalgia (muscle pain), headaches, dizziness, and various sensory disturbances, such as numbness or tingling sensations. These symptoms represent the core neurological challenges faced by a significant proportion of long COVID patients globally.
Sleep disturbances also presented a notable point of variation. A substantial portion of non-hospitalized long COVID patients in the U.S., nearly 60%, reported experiencing insomnia. This contrasts sharply with the roughly one-third or fewer of patients in Colombia, Nigeria, and India who indicated similar sleep problems. Such differences in sleep quality can have a profound impact on overall well-being, cognitive function, and daily functioning, further illustrating the multifaceted nature of long COVID’s lingering effects.
When the research team conducted a statistical analysis of the symptom patterns, a clear demarcation emerged between countries classified as high-income or upper-middle-income, such as the United States and Colombia, and those categorized as lower-middle-income, like Nigeria and India. This statistical divide reinforces the hypothesis that socioeconomic status and associated healthcare infrastructure play a significant role in how long COVID manifests and is reported by patient populations. The study’s methodology involved an observational design, enrolling adults who presented with persistent neurological symptoms following a COVID-19 infection between the years 2020 and 2025. Participants were recruited from the aforementioned four academic medical centers, encompassing both individuals who had been hospitalized and those who had not. To ensure comparability across regions, researchers utilized standardized neurological, cognitive, and quality-of-life assessments that were uniformly administered at each participating site.
The persistent impact of long COVID continues to be a global health concern, affecting millions worldwide. The condition is characterized by the continuation of symptoms for weeks, months, or even years after the initial SARS-CoV-2 infection has resolved. Current estimates suggest that a considerable percentage of adults, ranging from 10% to 30%, who contract COVID-19 go on to develop lingering symptoms, with cognitive and neurological issues being among the most disruptive and debilitating. As the study authors emphasize, long COVID disproportionately affects individuals in their prime working years, leading to significant detrimental consequences for the global workforce, productivity, and innovation.
In this particular study, patients in the United States consistently reported the greatest neurological and psychological burden. This heightened burden, as articulated by Dr. Koralnik, who also holds leadership positions at Northwestern Medicine’s Comprehensive COVID Center and the Havey Institute for Global Health, profoundly affected their quality of life and their capacity to engage in work. This underscores the substantial economic and personal toll that long COVID can exact, particularly in settings where reporting and access to care are more robust.
The findings from this extensive research carry significant implications for future approaches to understanding and managing long COVID. The researchers underscore the critical need for the development and implementation of culturally sensitive screening tools and diagnostic methodologies tailored to the specific contexts of diverse populations. Furthermore, the study highlights the imperative for robust healthcare systems capable of providing sustained long-term care and comprehensive follow-up for individuals grappling with the persistent effects of COVID-19. Building upon this foundational research, Dr. Koralnik and his international collaborators are actively engaged in testing cognitive rehabilitation treatments specifically designed for long COVID brain fog. These therapeutic interventions are currently being piloted in Colombia and Nigeria, employing identical treatment protocols that were initially developed for patients at the Shirley Ryan AbilityLab in Chicago. This collaborative effort aims to bridge the gap in treatment accessibility and effectiveness across different global settings, demonstrating a commitment to translating research findings into tangible improvements in patient care worldwide. The full findings of this pivotal study are detailed in a publication titled "A cross-continental comparative analysis of the neurological manifestations of Long COVID."
About the Author
